The use of antiplatelet agents in glomerulonephritis: a pharmacological approach

The use of antiplatelet agents in chronic glomerular disease is reviewed, with emphasis on drugs affecting thromboxane A2 synthesis or action. The results of short-term and long-term studies in human as well as animal models suggest a role for enhanced intrarenal synthesis of thromboxane A2, though not clearly defining the potential platelet vs glomerular targets of drug action. The availability of novel inhibitors and antagonists may provide new therapeutic strategies against thromboxane-A2-dependent loss of renal function.